Bank of America analysts have designated argenx SE (ARGX) and Vertex Pharmaceuticals (VRTX) as their leading large-cap biotechnology stocks for 2026. They assigned a price target of $1,013 to argenx, traded on Nasdaq as an ADR, and $598 to Vertex.

Argens shares currently trade at €613 on Euronext Brussels, where the analyst consensus target stands at €690, reflecting about 12% implied upside. Vertex shares are at $443 on Nasdaq, with a consensus target of $465. Bank of America's targets exceed these averages, signaling stronger conviction in both companies' prospects.

Bank of America points to robust sales of Vyvgart (efgartigimod) in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Expansion into earlier lines of therapy and accumulating real-world evidence support ongoing growth. Key near-term catalysts include phase 3 data for efgartigimod in myositis, expected in the third quarter, and empasiprubart in multifocal motor neuropathy in the fourth quarter.

For Vertex, the cystic fibrosis franchise continues to generate substantial cash flow, funding advances in other areas. Analysts highlight the rare kidney disease portfolio as a major long-term opportunity, particularly positive results for povetacicept in IgA nephropathy.

In the small- and mid-cap commercial category, Bank of America favors KalVista Pharmaceuticals (KALV) at $32 and Rhythm Pharmaceuticals (RYTM) at $149. KalVista's Ekterly gained approval in July 2025 as the first on-demand treatment for hereditary angioedema, while Rhythm's Imcivree became the initial therapy for acquired hypothalamic obesity in March.

Pre-commercial picks include Ocular Therapeutix (OCUL) at $27 and Bicara Therapeutics (BCAX) at $35.

These choices underscore a preference for biotechs with proven products alongside promising clinical milestones.